Background. Diaphragmatic fatigue is implicated as a cause of respiratory failure. This study was undertaken to evaluate the effects of inhaled olprinone, a newly developed phosphodiesterase III inhibitor, on the contractility of fatigued diaphragm in dogs.
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Phosphodiesterase (PDE) III inhibitors have been evaluated for therapeutic potential in the treatment of congestive heart failure. 1 2 In addition to these pharmacological properties, we have shown that amrinone, milrinone, and olprinone administered intravenously (i.v.) improve contractility of fatigued diaphragm that is implicated as a cause of respiratory failure, and that olprinone is most ef®cacious against diaphragmatic fatigue.
3±5 Recently, Myou and colleagues 6 have demonstrated that inhaled olprinone exhibits bronchodilater activity in asthmatic patients. However, there have been no reports investigating the effects of inhaled olprinone on contractility of fatigued diaphragm. The purpose of the present study was to examine the ef®cacy of inhaled olprinone for the improvement of diaphragm muscle function in dogs.
Methods
The procedure was approved by our animal research committee, and the care of animals was in agreement with guideline for ethical animal research. Twenty-four healthy mongrel dogs weighing 10±15 kg were anaesthetized with pentobarbitone (25 mg kg ±1 loading dose plus 2 mg kg ±1 h ±1 maintenance dose) i.v. to abolish spontaneous movement. Muscle relaxants were not used. Animals were placed in the supine position, their tracheas were intubated with a cuffed tracheal tube, and the lungs were ventilated mechanically with a mixture of oxygen and air (FI O 2 =0.4) to maintain Pa O 2 13.3 kPa, Pa CO 2 =4.7±5.3 kPa, and pHa=7.35±7.45. The right femoral artery was cannulated to monitor arterial pressure and to obtain blood gas samples for blood gas analysis. Arterial blood gas tensions were measured every 30 min. The right femoral vein was cannulated to administer uids (Ringer's lactate solution 10 ml ±1 kg ±1 h ±1 ), pentobarbitone and bicarbonate to maintain plasma HCO 3 ± concentration within normal range. Rectal temperature was monitored continuously and maintained at 37 (1)°C.
The phrenic nerves were exposed bilaterally at the neck, and stimulating electrodes were placed around them. Transdiaphragmatic pressure (Pdi) was measured using two thin-walled latex balloons: one positioned in the stomach, the other in the middle third of the oesphagus. Balloons were connected to a differential pressure transducer and an ampli®er. Supramaximal electrical stimuli (10±15 V) of 0.1 ms duration were applied for 2 s at lowfrequency (20 Hz) and high-frequency (100 Hz) stimulation with an electrical stimulator. The isometric contractility of the diaphragm was evaluated by measuring maximal Pdi after airway occlusion at FRC. Transpulmonary pressure (Ptp), the difference between airway and oesophageal pressures, was maintained by maintaining same lung volume before each phrenic stimulation. End-expiratory diaphragmatic geometry and muscle ®bre length during contraction were kept constant by placing a close-®tting plaster cast around the abdomen and lower one-third of the rib cage. Electrical activity of crural (Edi-cru) and costal (Edi-cost) parts of the diaphragm was recorded by two pairs of ®shhook electrodes placed through a midline laparotomy: electrodes were positioned into the anterior portion of crural part near the central tendon and the anterior portion of costal part (away from the zone of apposition) in the left hemidiaphragm. Each pair was placed in parallel ®bres 5±6 mm apart. The abdomen was then sutured in layers. The signal was recti®ed and integrated with a leaky integrator with a time constant of 0.1 s, and was regarded as the integrated diaphragmatic electrical activity (Edi-cru, Edicost).
Twenty-four dogs were randomly divided into three groups of eight each. After measuring the pre-fatigued (baseline) values of Pdi, Edi-cru, Edi-cost, and haemodynamic variables, in each group, diaphragmatic fatigue was induced by intermittent supramaximal bilateral electrophrenic stimulation applied for 30 min at a frequency of 20 Hz, an entire cycle of 4 s, and a duty cycle of 0.5 (i.e. low-frequency fatigue). 7 Olprinone 1 mg (group II), olprinone 2 mg (group III), or vehicle (group I) was inhaled from DeVilbiss 646 nebulizer (DeVilbiss Co., Somerset, PA, USA) operated by compressed air at 5 litre ±1 min ±1 . The nebulizer output was 0.14 ml min ±1 . The dose of olprinone chosen in this experiment was based on the study of Myou and colleagues. 6 Thirty minutes after the start of inhalation, in each group, Pdi, Edi-cru, Edi-cost, heart rate, and mean arterial pressure (MAP) were measured.
Values are mean (SD). Statistical analysis was performed by ANOVA for repeated measurements with Bonferroni's adjustment for multiple comparison and Student's t-test, where appropriate. A P value of <0.05 was considered signi®cant.
Results
No differences in haemodynamic variables and Pdi in the pre-fatigued (baseline) period were observed among the three groups. With an inhalation of olprinone in group III, increases in heart rate (P<0.05) and decreases in MAP (P<0.05) were observed. In groups I and II, there were no haemodynamic changes throughout the experiment (Table 1) .
Pdi values at different stages and changes of Edi-cru and Edi-cost (%Edi-cru and %Edi-cost, respectively) from baseline values are shown in Table 1 . Three groups were comparable with regard to Pdi to each stimulus during baseline condition. In each group, after producing fatigue, Pdi at low-frequency (20 Hz) stimulation decreased from baseline values (P<0.05), whereas Pdi at high-frequency (100 Hz) stimulation did not change. In groups II and III, Pdi at both stimulation frequencies increased from fatigued values (P<0.05) during olprinone inhalation. The increase in Pdi to each stimulus was larger in group III than in group II (P<0.05). In group I, the speed of recovery from fatigue was slower at 20 Hz stimulation than at 100 Hz stimulation. No changes in %Edi-cru and %Edi-cost were observed throughout the study in any group.
Discussion
The pressure generated by the diaphragm (Pdi) after a given electrical stimulus depends on its length and geometry. 8 A major determinant of length and geometry of the diaphragm is lung volume. In this study, lung volume was strictly controlled, because the airway was occluded at endexpiratory lung volume during the measurements and the end-expiratory Ptp was maintained constant before each stimulus. The deformation of thoracoabdominal structures was also avoided by placing a cast around the abdomen and lower one-third of the rib cage. Therefore, changes in Pdi observed in this experiment can be regarded as the result of changes in diaphragmatic contractility.
Hypoxaemia, hypercapnia, and metabolic acidosis decrease contractility of the diaphragm. 9 10 The Pa O 2 , Pa CO 2 , pHa, and HCO 3 ± concentration were controlled within normal ranges in this study. Therefore, these factors that could have affected diaphragmatic contractility were excluded. In addition, it has been reported that pentobarbitone, at the dose used in this experiment, does not affect diaphragmatic contractility. 11 This was also in accordance with our results in group I showing no change in Pdi.
Low-frequency fatigue is of particular clinical importance because the spontaneous, natural rate of phrenic nerve discharge is mainly in the low-frequency ranges (i.e. 5±30 Hz). 12 Therefore, the effect of inhaled olprinone on contractility in fatigued diaphragm induced by 20 Hz stimulation (i.e. low-frequency fatigue) was examined. Following a fatigue-producing period, in each group, Pdi at 20 Hz stimulation decreased from baseline values (P<0.05), whereas Pdi at 100 Hz stmulation did not change. The results of group I, in which Pdi was observed without inhalation of olprinone in fatigued diaphragm, showed that the speed of recovery from fatigue was relatively slower at 20 Hz stimulation than at 100 Hz stimulation, and also showed that Edi to each stimulus did not change. This was in agreement with previous studies by us.
3±5
PDE III inhibitorsÐincluding amrinone, milrinone, and olprinoneÐadministered i.v. at doses used clinically have been shown previously to increase contractility of fatigued diaphragm.
3±5 Amrinone (10 mg kg ±1 min ±1 ) increases Pdi by 55% at 20 Hz stimulation and by 9% at 100 Hz stimulation; milrinone (0.5 mg kg ±1 min ±1 ) increases Pdi by 69% and by 23% at each stimulus; olprinone (0.3 mg kg ±1 min ±1 ) increases Pdi by 85% and by 35% at each stimulus.
Thus, PDE III inhibitors affect Pdi at 20 Hz stimulation more when compared with Pdi at 100 Hz stimulation. We have no explanation for this difference, but olprinone is more effective than amrinone or milrinone for the augmentation of contractility in fatigued diaphragm. In the present study, Pdi at 20 and 100 Hz stimulation increased from fatigued values (P<0.05) when olprinone was administered by inhalation in groups II and III. The increase in Pdi at both stimuli was also larger in group III than in group II (P<0.05). These observations suggest that inhaled olprinone, in addition to i.v. olprinone, improves contractility of fatigued diaphragm, in a dose-related manner.
Diaphragmatic blood¯ow is an important determinant factor in diaphragm muscle function 12 and is also maintained relatively constant within a certain limit of perfusion pressure. 13 When MAP increases to >9.3 kPa, diaphragmatic blood¯ow is not reduced.
14 In this study, however, MAP <9.3 kPa was not observed with an inhlation of olprinone in groups II and III. Therefore, the decrease in MAP during olprinone inhalation would not affect diaphragmatic contractility. Additionally, cardiovascular effects were not evident in group II (no changes in heart rate and MAP) during olprinone inhalation while the effects on Pdi at both stimuli were signi®cant. This suggests that the action of inhaled olprinone on heart rate and MAP are not important for its effects on contractility in the fatigued diaphragm.
Olprinone, administered i.v., increases contractility of cardiac muscle by selectively inhibiting PDE III and accumulating cyclic AMP intracellularly, which, in turn, induces the activation of Ca 2+ transport from the sarcoplasmic reticulum.
14 In a previous report by us, 5 to clarify the mechanism responsible for the effects of olprinone administered i.v. on contractility of fatigued diaphragm, combined olprinone and nicardipine, a calcium antagonist which inhibits Ca 2+ in¯ux into diaphragmatic muscle, 15 was administered. Augmentation of Pdi by olprinone was abolished by administation nicardipine, suggesting that olprinone may increase contractility of fatigued diaphragm by in¯uencing Ca 2+ transport across the cell membrane. Why the fatigued diaphragmatic contractility was enhanced during olprinone inhalation is not known. The mechanisms of action of inhaled olprinone in the improvement of contractility in fatigued diaphragm may be similar to that of i.v. olprinone. However, further studies with inhaled olprinone and nicardipine are required. In summary, inhaled olprinone produced a dose-dependent improvement, in contractility of fatigued canine diaphragm.
